Render Target: STATIC
Render Timestamp: 2024-11-21T13:06:32.428Z
Commit: 5c4accf06eb7154018ba3f54329c7590f97f534a
XML generation date: 2024-09-30 01:57:41.232
Product last modified at: 2024-11-11T09:30:09.438Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

CXCL1/CXCL2 (E5M6D) Rabbit mAb #24376

Filter:
  • WB
  • IP

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 9
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:200

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    CXCL1/CXCL2 (E5M6D) Rabbit mAb recognizes endogenous levels of total CXCL1 and CXCL2 proteins. This antibody is more sensitive for detection of CXCL1 protein than CXCL2 protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with human CXCL1 recombinant protein.

    Background

    CXCL1 and CXCL2 (GRO-α and GRO-β) are two of the chemokines that act as ligands for the chemokine receptor CXCR2 (1). CXCR2 is expressed by several types of leukocytes and plays an important role in the recruitment of neutrophils to sites of inflammation (2). Although neutrophil recruitment is an important component of the innate immune system’s response to infection or injury, prolonged or excessive neutrophil recruitment can lead to inflammatory disease. Therefore, blocking CXCR2 has been pursued as a therapeutic approach for a variety of inflammatory diseases (3). In addition, CXCL1 and CXCL2 expression can be elevated in the tumor microenvironment, which contributes to tumor cell survival through enhanced angiogenesis and recruitment of immunosuppressive myeloid-derived suppressor cells (MDSCs) (4,5).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.